Oncotelic Therapeutics (OTCQB: OTLC), a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that Sapu Nano's investigational intravenous Deciparticle everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, scheduled for Dec. 9–12, 2025, in San Antonio, Texas. The presentation will showcase data on Sapu003, a novel Deciparticle formulation of everolimus designed to improve bioavailability, reduce toxicity, and enhance tumor penetration in HR⁺/HER2⁻ metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET).
Developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, Sapu003 represents a significant advancement in nanomedicine. The Deciparticle technology aims to address the limitations of conventional everolimus, including poor solubility and off-target effects. By encapsulating the drug in nanoparticles, Sapu003 enhances delivery to tumor sites, potentially improving efficacy while minimizing systemic side effects. This is particularly relevant for patients with HR⁺/HER2⁻ metastatic breast cancer, a common subtype where endocrine resistance often limits treatment options.
The acceptance of Sapu003 at the San Antonio Breast Cancer Symposium, a premier global conference, underscores the growing interest in nanoparticle-based therapies. The symposium brings together leading researchers, clinicians, and industry experts to discuss the latest advances in breast cancer research. Presentation of Sapu003 data at this venue could facilitate collaborations and accelerate clinical development. Oncotelic's CEO, Dr. Vuong Trieu, has filed over 150 patent applications and holds 39 issued U.S. patents, reflecting the company's strong intellectual property position in oncology.
Beyond Sapu003, Oncotelic benefits from its ownership stake in GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic's strategic focus. The company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. The presentation at the symposium is expected to provide critical insights into the safety and efficacy of Sapu003, potentially paving the way for further clinical trials.
For more information, the full press release is available at https://ibn.fm/wB4Hl. Updates on Oncotelic can be found in the company's newsroom at https://ibn.fm/OTLC.
